Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Sarcoma, Kaposi 1Respiratory Distress Syndrome 1Pneumonia 1Multi-centric Castleman's Disease 1Hematologic Neoplasms 1Glioblastoma 1Castleman Disease 1Astrocytoma 1Acquired Immunodeficiency Syndrome 1

Interventions

Zidovudine 9Interferon alpha-2 5Doxorubicin 5Vincristine 4Bleomycin 4pomalidomide 3Specimen Handling 3Nivolumab 3Magnetic Resonance Spectroscopy 3sargramostim 2liposomal doxorubicin 2interferon alfa-n1 2Etoposide 2Didanosine 2Biopsy 2Bevacizumab 2tocilizumab 1pembrolizumab 1halofuginone 1entinostat 1cabozantinib 1abemaciclib 1Zalcitabine 1Valganciclovir 1Therapeutics 1Sorafenib 1Psychiatric Rehabilitation 1Paclitaxel 1O-(Chloroacetylcarbamoyl)fumagillol 1Nicotine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Sarcoma, Kaposi × tocilizumab × Clear all
NCT01441063 2020-10-27

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
8 enrolled 18 charts
LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Castleman Disease, Sarcoma, Kaposi

Data powered by HemOnc (CC BY 4.0) Colophon âš¡